Senetek Appoints Pharmaceutical Industry Veteran Dr. Michael Delmage as Chief Technical Officer and Board Member Dr. Andreas Tobler as Chief Operating Officer & Managing Director, Europe
Wednesday October 16, 8:10 am ET
NAPA, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), www.senetekplc.com , today announced the appointments of Drs. Michael Delmage and Andreas Tobler as Chief Technical Officer and Chief Operating Officer & Managing Director, Europe, respectively. Initially, both appointees will be based in the Corporate Headquarters in Napa, California with Dr. Tobler relocating to London to head up Senetek's growing European operations.
"Senetek has conducted an extensive search for leaders with Drs. Delmage and Tobler's credentials," said Frank Massino, Senetek's Chairman and Chief Executive Officer. "I have had the pleasure of working side by side with Dr. Tobler over the past three years and have witnessed firsthand his outstanding contribution to Senetek in his role as a Board member. I have also had the benefit of working closely with Dr. Delmage in his role as a captive scientific consultant to Senetek. Both individuals recognize the tremendous potential for Senetek both in terms of technology and earnings growth."
Dr. Delmage was one of the founding executives of Santen International and member of the Board of Directors of Santen Oy who built a successful 500 person pharmaceutical company. At Santen, Dr. Delmage was responsible for the overall management of all Research and Development activities in the US and Europe from concept to regulatory approval. Dr. Delmage gained FDA approval of Santen's first two products in the US, beating industry average by 2.5 years. Since the founding of the company in 1994, Santen's sales of marketed US and European products grew to 100 million dollars. While at Chiron Ophthalmics, Dr. Delmage's accomplishments include the pioneering of the nation's first successful IND dealing with wound healing "growth factors" and initiating the first IND and subsequent development of tissue attachment factors as therapeutic agents. In addition, Dr. Delmage served as Program Director at Celtrix Pharmaceuticals where he successfully managed the first biotechnology product used clinically to treat retinal disease, with an on-time and on-budget progression from pilot pre-clinical studies to Phase III pivotal studies within three years.
Dr. Delmage received his Ph.D in Cellular and Molecular Biology from the University of Southern California, graduating Magna cum Laude; he was awarded a National Institute of Health Post Doctoral Fellowship in 1980. In 1986, Dr. Delmage earned an MBA from Pepperdine University in Los Angeles.
Dr. Tobler most recently held the position of Chief Executive Officer at Mediphore-Biotechnologie AG, Vienna/Krems, Austria which engaged in biopharmaceutical drug delivery and tissue engineering technologies. Dr. Tobler was responsible for the initial funding of Mediphore and managed the build-out of a pharmaceutical grade manufacturing facility in less than two years. Dr. Tobler's varied background include positions as CFO and Secretary at Nextgen Communications Corp., Northbrook, Ill., Managing Partner of the Royal Trust Bank (Switzerland), Zurich where he was responsible for Treasury, Capital Markets, Securities Trading, Project Finance as well as the management of the Tokyo office. From 1982 until 1988, Dr. Tobler held the positions of Vice President, Head Corporate Finance for Citibank/Citicorp, Zurich and Vice President, Head Capital Markets for Credit Suisse, New York. In addition, from 1980 to 1982, Dr. Tobler practiced law in Zurich, Switzerland with emphasis on corporate, commercial, banking and tax law.
Dr. Tobler received his doctoral law degree (LL.D.,Dr.iur) from the University of Zurich, graduating cum laude in 1978; in 1977, the Supreme Court of the Canton of Zurich admitted Dr. Tobler to the bar of Zurich. In 1980, he earned a Master of Comparative Jurisprudence from New York University, New York.
Senetek PLC is a biopharmaceutical company focused on developing and co-marketing products in the key skincare/dermatologicals and sexual dysfunction categories worldwide.
Visit Senetek PLC's web site: senetekplc.com .
Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: Pknopick@eandecommunications.com
Safe Harbor Statement:
This news release may contain statements that may be considered "forward-looking statements" under the Federal securities laws, including statements concerning the revenue and licensing income the Company may receive in the future under licenses of the Company's products, and the additional licensing agreements the Company may enter into during 2002. No forward- looking statement the Company makes is a guarantee of future performance or events. Actual results or events may differ materially from those in the forward-looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended June 30, 2002, filed with the Securities and Exchange Commission.
Make Your Opinion Count - Click Here
--------------------------------------------------------------------------------
Source: Senetek PLC |
